Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases by Pril, R.de et al.
  
 University of Groningen
Accumulation of aberrant ubiquitin induces aggregate formation and cell death in
polyglutamine diseases
Pril, R.de; Fischer, D.F.; Maat-Schieman, M.L.C.; Hobo, B.; Vos, R.A.I.de; Brunt, E.R.; Hol,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2004
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Pril, R. D., Fischer, D. F., Maat-Schieman, M. L. C., Hobo, B., Vos, R. A. I. D., Brunt, E. R., ... Leeuwen, F.
W. V. (2004). Accumulation of aberrant ubiquitin induces aggregate formation and cell death in
polyglutamine diseases. Human Molecular Genetics, 13(16), 1803-1813.
https://doi.org/10.1093/hmg/ddh188
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 20-05-2020
Accumulation of aberrant ubiquitin induces
aggregate formation and cell death in
polyglutamine diseases
Remko de Pril1, David F. Fischer1, Marion L.C. Maat-Schieman2, Barbara Hobo1,
Rob A.I. de Vos3, Ewout R. Brunt4, Elly M. Hol1, Raymund A.C. Roos2
and Fred W. van Leeuwen1,*
1Research Team Molecular Misreading, Netherlands Institute for Brain Research, Meibergdreef 33, 1105 AZ
Amsterdam, The Netherlands, 2Department of Neurology, Leiden University Medical Center, 2300 RC Leiden,
The Netherlands, 3Laboratory of Pathology East Netherlands, 7512 AD Enschede, The Netherlands and
4Department of Neurology, University Hospital Groningen, 9713 AW Groningen, The Netherlands
Received May 6, 2004; Revised and Accepted June 8, 2004
Polyglutamine diseases are characterized by neuronal intranuclear inclusions (NIIs) of expanded polygluta-
mine proteins, indicating the failure of protein degradation. UBB11, an aberrant form of ubiquitin, is a sub-
strate and inhibitor of the proteasome, and was previously reported to accumulate in Alzheimer disease
and other tauopathies. Here, we show accumulation of UBB11 in the NIIs and the cytoplasm of neurons in
Huntington disease and spinocerebellar ataxia type-3, indicating inhibition of the proteasome by polygluta-
mine proteins in human brain. We found that UBB11 not only increased aggregate formation of expanded
polyglutamines in neuronally differentiated cell lines, but also had a synergistic effect on apoptotic cell
death due to expanded polyglutamine proteins. These findings implicate UBB11 as an aggravating factor in
polyglutamine-induced neurodegeneration, and clearly identify an important role for the ubiquitin–proteasome
system in polyglutamine diseases.
INTRODUCTION
At least nine different neurodegenerative diseases are known
that are caused by the expansion of a CAG repeat in the
coding region of a transcribed gene, including the spinocere-
bellar ataxias (SCAs) and Huntington disease (HD) (1,2).
All these CAG expansion diseases are characterized by
progressive neuronal dysfunction starting during adult-life
and resulting in severe neurodegeneration. In the channelo-
pathy SCA6, neurodegeneration is caused by a small CAG
expansion (to 19–30 repeats) in a calcium channel subunit
that presumably causes a change of function (3). The other
eight diseases are probably caused by a gain of function of
the proteins carrying the expanded polyglutamine repeat.
The pathological repeat length for these genuine polygluta-
mine expansion disorders starts around 40 glutamine repeats
in the affected gene, with increasing severity and earlier mani-
festation upon greater expansion (1).
One of the hallmarks of the pathology of polyglutamine
diseases is the formation of neuronal intranuclear inclusions
(NIIs) in the affected areas of the brain (4). Although many
of the proteins carrying the polyglutamine repeat have a cyto-
plasmic function, upon polyglutamine expansion they all form
intranuclear inclusions that contain at least the expanded poly-
glutamine fragment. In HD, for instance, the NIIs contain only
the N-terminal part of huntingtin with the polyglutamine
stretch (4–7). The major pathological difference between the
polyglutamine diseases is the regional distribution of neurode-
generation. In HD, the striatum is the most severely affected
area and the cortex is affected to a lesser extent (8). In
SCA3, in contrast, neuronal degeneration occurs primarily in
the nuclei of the brainstem and the spinal cord (9). This
regional specificity is probably caused by differences in
expression levels of the respective disease genes among the
various brain regions or different vulnerability of various
types of neurons. In addition to the repeat expansion, other
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factors, such as proteasomal activity and expression or recruit-
ment of cellular chaperones, probably influence polyglutamine
toxicity and disease development (10–12).
NIIs contain ubiquitin or ubiquitinated proteins, which indi-
cates that the aggregating proteins are targeted to, but not
degraded by, the proteasome (4,13). Furthermore, in vitro
studies have shown that expanded polyglutamines can directly
inhibit the proteasome (14,15). In addition, in SCA3 patients,
subunits of the 26S proteasome have been shown to be
recruited to NIIs (16,17). Finally, in SCA1 transgenic mice,
the Purkinje cell pathology was aggravated by mutation of
the E6-AP ubiquitin ligase (18). All these findings point
towards an involvement of the ubiquitin–proteasome system
(UPS) in the pathogenesis of polyglutamine diseases and to
an enhancement of neurodegeneration by further impairment
of the UPS (19).
We previously reported that, in Alzheimer disease (AD), an
aberrant form of ubiquitin (UBBþ1) accumulates in the neuro-
pathological hallmarks of this disease (20). This UBBþ1
protein is formed by a dinucleotide deletion (DGU), leading
to a þ1 reading frame in the mRNA, and subsequent trans-
lation to a protein with an aberrant C-terminus. Thus far
UBBþ1 protein has been found in the hallmarks of several
neurodegenerative diseases, including AD and other tauo-
pathies, whereas it was not detected in synucleinopathies
and young control patients without pathology (20,21). The
aberrant transcript, however, in contrast to the protein,
appeared to be present even in young controls. Under
normal circumstances, neurons can apparently cope with
UBBþ1, and accumulation of this protein reflects proteasomal
dysfunction in different neuropathological disorders (21).
In vitro studies have shown that, although UBBþ1 can be
degraded by the proteasome (21,22), at higher concentrations
it inhibits proteasomal degradation of cellular proteins and
leads to cell death in neuroblastoma cells (23,24). In addition,
UBBþ1 has been implicated recently to mediate neurodegen-
eration via downstream interaction with the E2-25K ubiquitin
conjugating enzyme, which induces amyloid-b neurotoxicity
in vitro (25). In this perspective, UBBþ1 might accelerate
disease progression and increase the severity of the disease.
Notably, recent reports show that the proteasome activity is
indeed decreased in AD (26,27), strengthening the idea that
UBBþ1 accumulation is intimately related to impairment of
the proteasome (19).
Different findings point towards defective protein degra-
dation in polyglutamine diseases. We examined post-mortem
brain material of HD and SCA3 patients for the accumulation
of UBBþ1, as a marker for proteasomal impairment. More-
over, we used a cellular model for polyglutamine disease to
study the contribution of UBBþ1 to disease progression, i.e.
polyglutamine aggregation and cell death.
RESULTS
To identify NIIs in different brain areas of HD and SCA3
patients, we used antibodies against the N-terminal fragment
of the huntingtin protein or full-length ataxin-3, respectively
(Fig. 1A). In addition, we used an ubiquitin antibody and
the 1C2 antibody to identify the inclusions. SCA6 showed
staining of cytoplasmic aggregates with the a1A-subunit anti-
body (data not shown).
With antibodies against the UBBþ1 protein, we detected
immunopositive NIIs in the cortex (Fig. 1A) and striatum of
all HD patients (N ¼ 30). We found accumulation of UBBþ1
not only in adult-onset patients but also in juvenile HD
patients. Furthermore, we detected UBBþ1 immunopositive
NIIs in all SCA3 patients (N ¼ 6), in all the areas investigated
(Fig. 1A). Besides localization to the NIIs, we also found cyto-
plasmic staining for UBBþ1 in the affected neurons of HD and
SCA3 patients (Fig. 1A). In contrast, in the SCA6 patients
(N ¼ 2), we did not find any UBBþ1 staining in the affected
regions (data not shown). To ascertain whether UBBþ1 loca-
lizes to all or only to a subset of NIIs stained with 1C2, we
performed double immunofluorescent stainings on tissue sec-
tions of both HD and SCA3 patients. We found colocalization
of polyglutamine proteins and UBBþ1 in all the inclusions that
were found in juvenile as well as adult-onset HD and in SCA3
(Fig. 1B). Accumulation of UBBþ1 is thus not specific for HD,
but a general phenomenon found in polyglutamine diseases.
Besides being a marker for proteasome impairment, in vitro,
UBBþ1 inhibits the proteasome (22,24). Constructs with
expanded polyglutamine repeats can be used to mimic many
of the features of polyglutamine diseases in cell lines, includ-
ing aggregate formation and interaction with other proteins
(18,28–30).
To investigate the impact of UBBþ1 protein on aggregate for-
mation, we used plasmids with a truncated huntingtin fragment
containing 19, 38 or 43 glutamine repeats (HA–Q19–green
fluroscent protein (GFP), HA–Q38–GFP and HA–Q43–
GFP) in combination with plasmids containing either UBBþ1
or a lysine mutant of UBBþ1 (UBBþ1;K29,48R), which does
not inhibit the proteasome (22). Co-transfection of UBBþ1
with the normal Q19 polyglutamine length resulted in distri-
bution of polyglutamine protein throughout the cells and cyto-
plasmic staining for UBBþ1 (Fig. 2A). However, besides
accumulation of UBBþ1 in cells with expanded polyglutamine
proteins we found colocalization with the inclusions of both
the intermediate Q38 (Fig. 2B and C) and the expanded Q43
(Fig. 2D and E) polyglutamine proteins. The nuclear localiz-
ation of the aggregates in these cells was similar to that
observed in post-mortem brain material of the different polyglu-
tamine diseases. In addition, a number of cells display a clear
apoptotic morphology, with fragmented nuclei (Fig. 2C and
E), in agreement with previous findings for UBBþ1, or
expanded polyglutamines alone (23,30). In contrast to
UBBþ1, after transfection with UBBþ1;K29,48R we found no
colocalization with the aggregating polyglutamines (Fig. 2F;
Q43). It is remarkable that this latter ubiquitin mutant is not
incorporated in the inclusions, although cytoplasmic levels are
higher than that of UBBþ1 transfected cells (22).
For functional characterizations we used neuronally differ-
entiated human neuroblastoma cells (SH-SY5Y) (31). Cell-
proliferation markedly influences the aggregate formation
and cell death (32), which makes differentiated cells a more
useful model for functional assays. In our experiments,
HeLa cells showed comparable aggregate formation, but
much lower levels of cell death due to proliferation and sus-
ceptibility (data not shown).
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We quantified the aggregate formation after lentiviral trans-
duction of SH-SY5Y neuroblastoma cells with polyglutamine
vectors in combination with UBBþ1 or the double lysine
mutant of UBBþ1 (Fig. 3A). The truncated huntingtin frag-
ments with 38 or 43 glutamines show a marked increase in
aggregate formation under the influence of UBBþ1 in com-
parison with UBBþ1;K29,48R. Accumulation of UBBþ1 causes
an increase in polyglutamine protein and thus enhances the
aggregate formation. For the huntingtin fragment with 38 glu-
tamines, we even find a doubling of the number of aggregate
Figure 1. UBBþ1 colocalizes with polyglutamine proteins in HD and SCA3. (A) Staining of paraffin sections of the frontal cortex of a HD patient and the pons of a
SCA3 patient for UBBþ1 and, respectively, Htt-07 and a-ataxin-3. Pictures show staining of NIIs with UBBþ1, distinct from the nucleoli, in both polyglutamine
diseases. Magnification bar is 10 mm. (B) Double stainings show UBBþ1 staining in all inclusions positive for 1C2 in juvenile as well as adult onset HD and in
SCA3. Magnification bar is 50 mm. Note also the cytoplasmic staining for UBBþ1 in both disorders, (A) and (B).
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Figure 2. UBBþ1 colocalizes with expanded polyglutamines in vitro. HeLa cells co-transfected with plasmids with a truncated huntingtin fragment containing
19, 38 or 43 glutamine repeats (HA–Q–GFP) together with constructs for UBBþ1 or UBBþ1;K29,48R, were fixed 4 days post-transfection. All cells that were
transfected with the construct containing 19 glutamines showed a diffuse cellular polyglutamine staining [(A), green; left panel]. Constructs with 38 and
43 glutamine repeats result in the formation of multiple polyglutamine aggregates [respectively, (B) and (C), and (D), (E) and (F); green; left column]. Co-transfec-
tion with UBBþ1 gave cytoplasmic staining for UBBþ1 (A)–(E) (in red; middle column) with all constructs. In addition, UBBþ1 co-aggregates with the polyglu-
tamine constructs Q38 (B and C) and Q43 (D and E), whereas UBBþ1;K29,48R only shows cytoplasmic staining despite aggregate formation of Q43 (F). The right
column shows the overlay of UBBþ1 and polyglutamine, with faint To-Pro nuclear staining in blue. Magnification bar is 10 mm.
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forming cells due to UBBþ1 from 4 days onwards (Fig. 3A).
Statistical analysis by three-way analysis of variance
(ANOVA) confirmed a highly significant correlation between
the aggregate formation, the influence of UBBþ1 and the time
course (P , 0.001). Immunofluorescent stainings furthermore
show a preferential accumulation of UBBþ1 in the cells with
the expanded huntingtin fragments (Fig. 3B). Quantification
of the cells 4 days after infection showed a clear increase in
the amount of UBBþ1 expressing cells upon expansion of
the polyglutamine repeat (Fig. 3B). Statistical analysis by
one-way ANOVA confirmed a significant correlation
between the repeat expansion and UBBþ1 accumulation
(P ¼ 0.001).
We made cell lysates 6 days after infection and analyzed
these by western blotting (Fig. 4). Western blots probed with
an anti-HA antibody showed, owing to UBBþ1, a 3-fold
increase in sodium dodecyl sulfate (SDS)-insoluble aggregate
fraction at the top of the gel with both 38 and 43 glutamines
(Fig. 4A). The amount of soluble polyglutamine protein,
however, shows only a slight increase for all repeat lengths
(Fig. 4B). The bars (Fig. 4D) represent the relative amount
of aggregates (Fig. 4A) after correction for b-actin (Fig. 4C).
Statistical analysis by two-way ANOVA confirmed that
UBBþ1 has a pronounced, highly significant synergistic
effect on the aggregate formation of constructs with 38 and
43 glutamines (P , 0.001).
To investigate the effect of the expression of the different
proteins on the viability of neuroblastoma cells, we performed
a cell survival assay (Fig. 5). The scatter plots show a
representative FACS analysis of the polyglutamine expressing
cells (Fig. 5A). Dead cells show a marked increase in red-
fluorescence due to conversion of the reactive dye (higher
population). Cell death due to Q19 represents the background
level of cell death due to infection and culturing of the cells,
whereas Q19 itself is not toxic (28). Combination of Q19
with UBBþ1;K29,48R, which was used as a control, does not
affect cell death. Expansion of the polyglutamine repeat
resulted in a moderate increase in cell death when combined
with UBBþ1;K29,48R. We measured a small but significant
increase for the plasmid with 38 glutamines, whereas the
expansion to 43 glutamines caused a significant 3-fold
increase in cell death. Upon addition of UBBþ1, a moderate
and significant increase in cell death was found for the Q19
construct. In contrast to previous experiments (23), lentiviral
transduction resulted in only moderate cell death for UBBþ1
(Fig. 4B) due to degradable levels of UBBþ1 protein (21).
However, UBBþ1 in combination with longer glutamine
repeats caused a much more pronounced increase in cell
death for Q38 as well as for Q43 constructs. Statistical analy-
sis by two-way ANOVA confirmed that the combination of
UBBþ1 with constructs of 38 and 43 glutamines has a pro-
nounced, highly significant synergistic effect on the cell
death mechanism (P , 0.001). This synergistic effect mani-
fests itself as an increase of the absolute effect of UBBþ1
on cell death with increasing length of the huntingtin frag-
ment. Caspase inhibition by Ac-DEVD-CHO resulted in
a marked decrease in cell death in our polyglutamine
model, indicating that cell death due to UBBþ1 as well
Figure 3. UBBþ1 induces aggregate formation and preferentially accumulates with expanded polyglutamines. Differentiated SH-SY5Y neuroblastoma cells were
lentivirally infected with constructs with truncated huntingtin fragments containing 19, 38 or 43 glutamine repeats (HA–Q–GFP) in combination with either
UBBþ1;K29,48R (KR) or UBBþ1 (þ1). Cells were quantified for aggregate formation every 24 h after infection (A). Note that huntingtin with 19 glutamines
does not result in the formation of aggregates, resulting in two overlapping lines in this graph. Constructs with 38 and 43 glutamines both show a marked increase
in the number of aggregate forming cells in the presence of UBBþ1, as represented by the two uppermost lines. Statistical analysis by three-way ANOVA demon-
strated a strong correlation between the aggregate formation of expanded polyglutamines, the influence of UBBþ1 and the time course (P , 0.001). Expression
of UBBþ1 was quantified 4 days after infection (B). The expression of expanded huntingtin fragments causes a preferential accumulation of UBBþ1 in these cells.
Statistical analysis by one-way ANOVA showed a highly significant correlation between repeat expansion of the huntingtin fragments and the UBBþ1 accumu-
lation (P ¼ 0.001). All experiments were performed in triplicate.
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as due to expanded polyglutamines occurs via an apoptotic
pathway (Fig. 4B). The percentage of cell death with
caspase inhibitor did not significantly increase above the back-
ground level.
DISCUSSION
Previously we reported that the accumulation of UBBþ1 in
tauopathies is a marker for proteasomal dysfunction (21).
Here, we show that this accumulation is not only indicative
of proteasome impairment, but that UBBþ1 apparently also
contributes to the pathogenesis of polyglutamine diseases.
The accumulation of UBBþ1 protein enhances aggregate for-
mation in a cellular model of polyglutamine disease. In
addition, the toxicity of UBBþ1 in combination with expanded
polyglutamines is not just additive but clearly works synergis-
tically. It thus suggests that both toxic proteins somehow inter-
vene with the same or analogous pathways to compromise
cellular function, and eventually cause cell death.
Molecular misreading of the UBB gene is a general process
that occurs both in neurological diseases and in control indi-
viduals (21). We performed a ligase chain reaction (LCR),
as described earlier (21), to confirm the presence of
UBBDGU transcripts in the mRNA from frontal cortex tissue
of three different HD patients (data not shown). The GU
deletion was present in all HD patients tested, indicating
that at the level of the mRNA there is no difference between
HD patients, non-demented controls or any of the previously
tested neurological diseases (21). Differences in UBBþ1 stain-
ing are probably the result of decreased proteasomal activity
due to disease-related proteins or ageing (5,21,26,27,33).
Neurological diseases such as Parkinson disease, in which
impairment of the proteasome is not demonstrated, do not
lead to UBBþ1 accumulation (21,34).
Both HD and SCA3 form NIIs, and we demonstrated here
that, independent of their protein context (huntingtin and
ataxin-3, respectively) these aggregates contain UBBþ1
(Fig. 1). Moreover, UBBþ1 not only localizes to the inclusions;
the cytoplasmic immunoreactivity for this aberrant protein is
increased as well (Fig. 1A), indicating high protein levels
that potentially impair the proteasome. Accumulation of
UBBþ1 reflects in vivo proteasomal impairment in the poly-
glutamine disorders, which is in agreement with previous in
vitro results (14–16). What is striking is the accumulation
of UBBþ1 in all tested HD and SCA3 patients, irrespective
of polyglutamine length and age, showing that UBBþ1 can
already accumulate at a young age (Fig. 1B). The high stab-
ility of ubiquitinated UBBþ1 contributes to the accumulation
in neurodegenerative disease, and it has been suggested that
even low levels of misreading can result in toxic protein
levels (24). We did not find UBBþ1 in SCA6, suggesting
proper functioning of the proteasome in this channelopathy.
Indeed, the proteasome has not been implicated in disease pro-
gression in SCA6, and the inclusions, which are only present
in the cytoplasm, are not ubiquitinated (35).
Although the mechanism by which different cellular pro-
teins are recruited into NIIs is unknown, the presence of
UBBþ1 in NIIs in human tissue and in a cellular model impli-
cates a similar mechanism. Accumulation of UBBþ1 will
probably start in the cytoplasm, followed by translocation
into the NIIs. Interestingly, we showed that ubiquitination
on lysine 29 or 48 is not only required for degradation of
UBBþ1, in agreement with previous results (22), but is also
needed for its translocation to the inclusions. Polyubiquitin
chains of targeted proteins are bound to the S6a regulatory
subunit of the 19S cap, and it is likely that both the UBBþ1
resistance to degradation and its proteasomal impairment
resemble binding to this subunit, but lack of processing
through the 20S core (24,36). Components of the proteasome,
and especially the 19S cap structure, have been shown to be
present in NIIs and could thus explain the localization of
UBBþ1 into the inclusions (16,17).
In addition to human brain material, we also found accumu-
lation and co-aggregation of the proteasome substrate UBBþ1
with expanded polyglutamines in a cellular model (Fig. 2).
Moreover, the proteasome inhibitor UBBþ1 causes an increase
in aggregate formation of expanded polyglutamines (Figs 3A
and 4). The expanded polyglutamine proteins reciprocally
result in the preferential accumulation of UBBþ1 in these
cells (Fig. 3B). We suggest that inhibition of the degradation
machinery is central to the development of polyglutamine dis-
eases and causes accumulation of different aberrant proteins.
We demonstrated that, UBBþ1 not only increases aggregate
formation, but also has a synergistic effect on apoptotic cell-
death by expanded polyglutamines (Fig. 5). Ubiquitinated
Figure 4. UBBþ1 increases aggregate formation of expanded polyglutamines.
Differentiated SH-SY5Y neuroblastoma cells were lentivirally infected with
constructs with truncated huntingtin fragments containing 19, 38 or 43 gluta-
mine repeats (HA–Q–GFP) in combination with either UBBþ1;K29,48R (KR)
or UBBþ1 (þ1), and harvested 6 days after infection. (A) Especially with
38 glutamines a marked increase is seen in the SDS-insoluble aggregate frac-
tion that is retained at the top of the gel when cells are co-infected with
UBBþ1. The irregular appearance of the SDS-insoluble fraction is caused by
the intrinsic property of the aggregates that hardly run into the stacking-gel
of the western blot. (B) The levels of soluble polyglutamine protein show a
minor increase (around 60 kDa). (C) b-Actin staining as a loading control.
(D) Bars show the relative integrated optical densities of the aggregate fraction
after correction for loading. Statistical analysis by two-way ANOVA showed a
strong synergistic effect of UBBþ1 on aggregate formation by expanded poly-
glutamines (P , 0.001). All experiments were performed in triplicate.
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UBBþ1 and expanded polyglutamine proteins have been shown
to inhibit the proteasome in vitro (14,15,22), and we demon-
strated here that both factors enhance the effect of the other
aberrant protein. The mutual decrease of proteasome activity
probably leads to further accumulation of aberrant proteins,
and eventually cell death. The fact that ubiquitination of
UBBþ1 is required for its proteasomal inhibition (22), its toxi-
city (23) and its contribution to aggregate formation and poly-
glutamine-induced cell death suggests that polyubiquitination is
a prerequisite for both aggregate formation and cell death.
Although the genetic basis of polyglutamine diseases is
known, a number of questions remain unanswered as to the
Figure 5. UBBþ1 synergistically aggravates polyglutamine-induced cell death. Cell death of differentiated SH-SY5Y neuroblastoma cells, as assessed by a cell
survival assay 6 days after infection, with constructs with 19, 38 or 43 glutamines (HA–Q–GFP) in combination with UBBþ1;K29,48R (KR) as a control or
UBBþ1 (þ1). (A) Polyglutamine–GFP positive cells were analyzed by flow cytometry for conversion of red-fluorescent dye (representative FACS analysis).
Scatter plots clearly show the differential distribution of living cells (lower population) and dead cells (higher population; bright red-fluorescent). (B) The
bars show the percentage of cell death that was observed under different conditions. Q19 shows the background percentage of cell death due to infection or
culturing and no increase was observed in combination with UBBþ1;K29,48R (B). The horizontal line signifies the percentage of background cell death. A
minor increase in cell death was observed with expansion of the polyglutamine repeat. Co-infection with UBBþ1 caused a small increase in cell death of
Q19, but a marked increase was observed with constructs of both 38 and 43 glutamines. Statistical analysis by two-way ANOVA indeed showed a strong syner-
gistic effect of UBBþ1 on cell death by expanded polyglutamines (P , 0.001). Caspase inhibition with Ac-DEVD-CHO resulted in a marked decrease of cell
death due to UBBþ1 as well as due to expanded polyglutamines. Statistical analysis revealed no significant increase in cell death in comparison with the back-
ground level. All experiments were performed in triplicate.
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precise cause of toxicity and whether aggregates are either
beneficial or toxic (37). Even between individuals with
similar repeat length, there are differences as to the age at
onset, the progression, and the extent of atrophy (1,8,38,39).
Recent reports indicate that genetic and familial factors
account for a great deal of variation of the age at onset in
HD (12,40). Possible candidates include proteasome subunits
and cellular chaperones (10,11) and, as described in the
present paper, also factors such as UBBþ1 can act as modifiers
of both the onset and severity of the disease.
From the present study it is evident that UBBþ1 not only
accumulates in polyglutamine diseases, indicating impairment
of the proteasome, but probably plays a role in neurodegenera-
tion itself. In addition to co-aggregation with polyglutamine
proteins, ubiquitinated UBBþ1 synergistically aggravates
polyglutamine-induced aggregate formation, and especially
cell death. Targeting of UBBþ1 to the proteasome by ubiqui-
tination is thereby required for degradation, toxicity and
colocalization with the NIIs. Consequently, the accumulation
of UBBþ1 in HD and SCA3 post-mortem tissue, in both
the inclusions and the cytoplasm of neurons, implicates
UBBþ1 as an aggravating factor in polyglutamine-induced
neurodegeneration, and clearly identifies an important role
for the UPS in polyglutamine diseases. These results indicate
that proteasomal activation or removal of its blockades




Autopsy material was obtained from the Huntington bank
(Leiden University Medical Center, The Netherlands) for
HD cases, and the Laboratory of Pathology East Netherlands
(Enschede, The Netherlands) and University Hospital Gronin-
gen (Groningen, The Netherlands) for SCA cases (Table 1).
We analyzed striatal tissue from four different HD patients
and frontal cortex tissue of 30 HD patients with polyglutamine
expansion of various lengths. Furthermore, we examined the
hippocampus, pons, mesencephalon and medulla oblongata
of six different SCA3 patients and the hippocampus and cer-
ebellum of two SCA6 patients. All brain areas were fixed in
formaldehyde and subsequently embedded in paraffin.
Immunohistochemistry
Paraffin sections (6 mm) were immunohistochemically labeled
with different antibodies using the peroxidase–anti-peroxidase
method with nickel intensification as described previously
(20). The 1C2 monoclonal antibody against expanded polyglu-
tamine repeats (1:10 000; Chemicon, Temecula, USA) (41),
polyclonal Htt-07 antiserum against the N-terminus of
huntingtin (1:100) (7), polyclonal anti-ataxin-3 antibody
(1:2000) (42) and polyclonal A6RPT-C against the C-termi-
nus of the a1A-subunit of the voltage-dependent calcium
channel (1:100) (35) were used for the detection of
the respective disease proteins. UBBþ1 was detected using
antisera against the C-terminal part of the protein [Ubi2A,
1:1000, bleeding 020698 and Ubi2þ 1, 1:1000, bleeding
010994; see literature for details on epitope and specificity
(20,21)].
For double stainings, we subjected paraffin sections to
irradiation with a broad spectrum lamp for at least 24h
to reduce autofluorescence (43,44). We then deparaffinized
sections and incubated them with the first antibodies overnight
in a humid chamber at 48C. We enhanced the UBBþ1 signal
using the avidin–biotin–complex (Vector Laboratories,
Burlingame, USA) and tyramine procedure (45) (Sigma–
Aldrich, St Louis, USA) and stained with streptavidin-
conjugated-Cy5 (Jackson Laboratories, West Grove, USA).
1C2 was directly visualized using donkey-anti-mouse-Cy2.
Signal specificity was demonstrated by swapping fluorescent
dyes and omission of primary antibodies to exclude aspecific
staining or signal enhancement. Images were obtained using
a confocal laser scanning microscope (Zeiss 510).
Cell lines
HeLa cells were cultured in low-glucose Dulbecco’s modified
Eagle medium containing 10% fetal calf serum (FCS), sup-
plemented with 100 U/ml penicillin and 100 mg/ml streptomy-
cin (all Invitrogen, Grand Island, NY). Cells were cultured on
0.2% gelatin-coated glass coverslips in 24-well plates (Nunc,
Roskilde, Denmark) 1 day before transfection.
SH-SY5Y neuroblastoma cells (ATCC:CRL-2260) were
cultured in high-glucose Dulbecco’s modified Eagle medium
containing 15% FCS, supplemented with 100 U/ml penicillin
and 100 mg/ml streptomycin (all Invitrogen). Cells were cul-
tured in 6-well plates (Nunc) 1 day before infection.
Transfections
We performed transfections with the calcium-chloride
method, using 0.5 mg plasmid DNA of each of the respective
plasmids for 24-well plates (46). Polyglutamine plasmids
containing a truncated huntingtin fragment with different poly-
glutamine repeats (19,38,43) flanked by a HA tag and GFP
reporter sequence were provided by Dr de Christofaro (28).
Vectors for ubiquitin, UBBþ1 and a lysine mutant of UBBþ1
in which both lysine 29 and 48 are mutated into an arginine
residue (UBBþ1;K29,48R) were described earlier (22).
Cells were fixed 4 days after transfection and stained for
UBBþ1 [Ubi3, 1:500, bleeding 050897 (23)]. Subsequently
cells were incubated with donkey-anti-rabbit-Cy3 (1:200;
Jackson Laboratories) and ToPro-3 nuclear staining (1:200,
Molecular Probes, Leiden, The Netherlands). After staining
for UBBþ1, pictures were obtained using a confocal laser
scanning microscope (Zeiss 510).
Infections
cDNAs for UBBþ1, UBBþ1;K29,48R, HA–Q19–GFP, HA–
Q38–GFP and HA–Q43–GFP were cloned in the lentiviral
transfer plasmid pRRLsin-PPThCMV-GFP-pre (46). VSV-G
pseudotyped lentivirus was produced by co-transfection of
the transfer plasmid and helper plasmids (pCMVdeltaR8.74
and pMD.G.2) in 293T cells. Medium was harvested 24 and
48 h after transfection and concentrated by ultracentrifugation.
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Virus pellets were resuspended in phosphate buffered saline
(PBS) containing 0.5% bovine serum albumin (BSA)
(Sigma). Stocks were titered with a HIV-1 p24 coat protein
ELISA (NEN Research, Boston, USA). Lentiviral vectors
were used to infect SH-SY5Y neuroblastoma cells at a multi-
plicity of infection of 50.
Quantification of cells
For aggregate formation, cells were counted manually every
24 h after infection. The percentage of polyglutamine expres-
sing cells with aggregates was quantified over three randomly
selected fields per experiment. Experiments were performed
in triplicate and statistics was performed using three-way
ANOVA, testing the interaction between repeat expansion,
UBBþ1 protein expression and time course.
UBBþ1 immunopositive cells, were counted after fixation
and immunofluorescent staining for UBBþ1. The percentage
of polyglutamine expressing cells positive for UBBþ1 was
quantified over three randomly selected fields per experiment.
Experiments were performed in triplicate and statistics was
done using one-way ANOVA, testing the significance of
repeat expansion on UBBþ1 accumulation.
Western blots
We harvested neuroblastoma cells (SH-SY5Y) 6 days after
infection in cold PBS. Cell pellets were resuspended in
Table 1. Clinicopathological information of Huntington, SCA3 and SCA6 patients












1 11 F 21 1240 21 22–84 3 Frontal cortex
2 20 F 36 860 21 17–86 4 Frontal cortex
3 33 F 144 1220 122 20–52 3 Frontal cortex
4 39 M 10 NA 363 15–59 4 Frontal cortex, striatum
5 40 M 16 1400 124 10–41 3 Frontal cortex
6 41 F 24 1150 42 16–46 3 Frontal cortex, striatum
7 49 M 120 1120 186 21–51 4 Frontal cortex
8 49 F NA NA 186 17–47 3 Frontal cortex
9 50 M 4 1230 31 20–47 3 Frontal cortex
10 51 M 4 1260 2 27–45 3 Frontal cortex
11 51 F 5 900 14 19–46 4 Frontal cortex
12 51 F 74 1100 NA 15–43 3 Frontal cortex
13 52 F 20 840 31 16–53 4 Frontal cortex
14 55 M 24 1250 124 22–47 2–3 Frontal cortex
15 56 M 32 1250 2 18–49 3 Frontal cortex
16 57 F 72 1200 162 16–43 3 Frontal cortex
17 58 F 34 1170 7 24–43 3 Frontal cortex
18 60 M 12 1200 248 20–43 3 Frontal cortex
19 60 M NA NA 35 26–47 4 Frontal cortex
20 61 F 17 1050 NA 17–45 3 Frontal cortex
21 61 F 24 840 21 21–47 4 Frontal cortex
22 62 M 12 1200 62 20–43 3 Frontal cortex
23 63 F 10 1100 58 17–45 3 Frontal cortex, striatum
24 64 F 60 1080 7 19–42 3 Frontal cortex
25 66 M 28 1125 78 21–40 3–4 Frontal cortex
26 66 F NA 950 107 20–44 3–4 Frontal cortex, striatum
27 68 F 12 1130 62 20–42 3 Frontal cortex
28 69 F 24 NA 155 21–40 3 Frontal cortex
29 69 M 48 1200 62 16–42 3 Frontal cortex
30 76 M 14 970 81 15–46 3 Frontal cortex
SCA3a
31 34 M NA 1598 28 20–75 Medulla oblongata
32 51 M 24 1244 21 27–72 Hippocampus, mesencephalon
33 59 F 12 1290 21 20–72 Hippocampus, pons
34 62 M 21 1236 21 23–70 Hippocampus, pons
35c 65 M ,12 1258 28 27–72 Pons
36c 66 M 14 1220 21 24–70 Pons
SCA6a
37 69 M 46 1395 28 b Hippocampus, cerebellum
38 76 M 24 1418 120 22 Cerebellum
aAll cases positive with htt-07, ataxin-3 and A6RPT-C, respectively.
bNot available, but most probably 21 or 22.
cBrothers.
NA, not available.
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lysis-buffer (1% NP40, 0.1 M NaCl, 0.01 M Tris–HCl
pH 8.0, 1 mM EDTA pH 8.0) containing protease inhibitors;
1 mM PMSF and 10 mg/ml leupeptin. We performed cell
lysis at 48C for 30 min and passed samples through a 25G
needle to ensure complete lysis. All samples were loaded
onto SDS–PAGE gels and transferred semi-dry onto nitrocel-
lulose (Schleicher and Schuell, Dassel, Germany). Polygluta-
mine proteins were detected using a monoclonal antibody
directed against the HA tag (12CA5, 1:100, culture
supernatant) (47). Blots were additionally probed with a
monoclonal b-actin antibody (JLA2.0, 1:500; Developmental
Studies Hybridoma Bank, Iowa, USA) as a control for the
amount of cell-lysate loaded. Subsequently, blots were incu-
bated with anti-mouse HRP (1:1000; DAKO, Glostrup,
Denmark) followed by Lumilight ECL (Perkin Elmer,
Norwalk, USA) chemiluminescence. The integrated optical
density of the bands was determined by image analysis with
Image Pro Plus and after correction for b-actin the value for
Q43 with UBBþ1 was set to 1 to obtain the relative ratios.
Cell survival assay
We assessed SH-SY5Y cell survival using a Life-Deadw kit
(red-fluorescence; Molecular Probes, Leiden, The Nether-
lands) and analyzed the cells on a flow cytometer (Becton
Dickinson, Palo Alto, USA) according to the manufacturers
protocol. In short, we harvested lentivirally infected cells
(see before) 6 days after infection using 0.25% trypsin (Invi-
trogen), washed in PBS and incubated them for 30 min with
the fluorescent reactive dye. Subsequently, we fixed cells
with 4% formaldehyde for 15 min and resuspended in PBS–
BSA (1  PBS pH 7.6, 0.5% BSA, 0.1% NaN3). We analyzed
polyglutamine–GFP expressing cells by flow cytometry for
conversion of the Life-Deadw kit reactive dye. At least 104
polyglutamine–GFP positive cells were examined per
sample. Dead cells showed a marked increase of
red-fluorescence over living cells due to conversion of the
dye (Fig. 4A). Experiments were performed in triplicate and
statistics were done using two-way ANOVA, testing the inter-
action between UBBþ1 protein expression and repeat expan-
sion. Caspase inhibition was performed by addition of
100 mM Ac-DEVD-CHO (Sigma) to the culture medium
every 2 days.
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